INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2012

Omega-3 fatty acids did not prevent cognitive decline in coronary heart disease patients.

In a randomized, double-blind, placebo-controlled trial, 2,911 coronary patients aged 60 to 80 years received margarines delivering 400 mg/day EPA-DHA, 2 g/day ALA, both, or placebo for 40 months. Changes in Mini-Mental State Examination scores did not differ between EPA-DHA and placebo (-0.65 vs -0.69 points, P = .44) or ALA and placebo (-0.60 vs -0.74 points, P = .12). Risk of cognitive decline was 1.03 (95% CI: 0.84-1.26) for EPA-DHA and 0.90 (95% CI: 0.74-1.10) for ALA.

Study type
Randomized controlled trial
Who was studied
2,911 coronary heart disease patients aged 60 to 80 years
What was measured
Global cognitive decline and Mini-Mental State Examination score

THE PAPER

Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients.

Geleijnse JM, Giltay EJ, Kromhout D. Alzheimers Dement, 2012.

PubMed 21967845 ↗DOI 10.1016/j.jalz.2011.06.002 ↗

Heart & arteriesNutrients & adequacyBrain & moodHealthy aging & longevity

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.